spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Helsinn Group 

 HSMN NewsFeed - 20 Apr 2018
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Dec 2016
Helsinn Integrative Care Announces 510(K) FDA Clearance for Medical Device Xonrid(R) Gel
Devices Oncology Dermatology FDA Product Launch
 HSMN NewsFeed - 10 Oct 2016
OncoResponse Secures $7M in Supplemental Series A Funding
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 16 Feb 2016
Helsinn Group Signs Exclusive Agreement With Mundipharma for the Distribution and Licence of Anamorelin in Northern Europe Countries
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 3 Sep 2015
Helsinn Group Signs Exclusive Agreement With Mundipharma for the Distribution and Licence of anamorelin in Switzerland and Liechtenstein
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 27 May 2015
The European Commission Approves ALOXI(R) (palonosetron HCl) Injection to Prevent Nausea and Vomiting Due to Chemotherapy in Children as Young as One Month
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Oct 2014
FDA Approves AKYNZEO(R) (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Oct 2012
DARA BioSciences Launches Soltamox(R), First and Only Liquid Version of Tamoxifen Citrate
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Sep 2009
New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Group's American subsidiary, Helsinn Therapeutics (U.S.) Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jun 2009
Single Dose Palonosetron Prevents Emesis Induced by Chemotherapy in Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jan 2009
Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Nov 2008
Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
Biopharmaceuticals Oncology
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.